Abbott provides a choice of heart failure tests, offering both BNP and NT-proBNP biomarkers to aid in diagnosis and assessment of severity of heart failure.
For in vitro diagnostic use only.
Abbott’s range of high-performance tests are free from biotin interference and enable identification of levels of Galectin-3 and NP, in combination with clinical assessment, to help define a clinical pathway that improves accurate diagnosis and optimizes patient care.2-9
Heart failure has a complex presentation and can be difficult to diagnose due to non-specific symptoms, such as shortness of breath.10-13
Misdiagnosis can lead to morbidity and in-hospital mortality and re-admission rates are high.11,12
Heart failure results in significant clinical, societal and economic burdens globally.
More accurate assessment is vital for optimizing resources and improving patient outcomes.14
64.3 million people live with heart failure worldwide15
>1 million hospitalizations in both US and Europe16
1 in 4 patients are re-hospitalized within 30 days.17
44% patients re-hospitalized within 60 days17
The Alinity i BNP assay is to be used as an aid in the diagnosis and assessment of severity of heart failure.2,3*
The Alere NT-proBNP assay can aid diagnosis of individuals suspected of having congestive heart failure and assessment of heart failure severity.4,5*
The Alinity i Galectin-3 assay can be used in conjunction with clinical evaluation as an aid in assessing the prognosis of patients with chronic heart failure.7
*If BNP or NT-proBNP results are not consistent with other clinical observations, additional information may be required for diagnosis.
Our physician resource provides further information on how Abbott’s BNP and NT-pro BNP tests aid in the diagnosis and assessment of congestive heart failure.
Both BNP and NT-proBNP levels have been shown to accurately reflect heart failure severity, correlating well with the New York Health Association (NYHA) classification.18 With one diagnostic cut off for all ages, BNP is simpler to interpret. BNP has a narrower clinical grey zone so fewer patients have indeterminate values.12 Patients with heart failure often have renal dysfunction. BNP results are less affected than NT-proBNP by renal dysfunction, as NT-proBNP is solely cleared through the kidneys.12
For BNP, all manufacturers currently suggest a single-decision cut off of 100 pg/mL.12
For NT-proBNP, multiple age-related cut offs are used:4
125 pg/mL < 75 yrs
450 pg/mL ≥ 75 yrs
ICON study recommends several cut offs for NT-proBNP:19
Rule out:
300 pg/mL
Rule in:
450 pg/mL < 50 yrs
900 pg/mL 50-75 yrs
1800 pg/mL > 75 yrs
* Age gray zone: age over 50 years or renal dysfunction.
† Clinical gray zone: other non-heart failure conditions may be contributing to elevation.
Adapted from McCullough et al, 2009.
Explore how High Sensitive Troponin can help to more accurately identify your patients' risk of a future cardiac event.
Instill confidence in your cardiac care decision making with our comprehensive cardiac assay menu.
Find the latest information in laboratory science, therapeutic areas and Abbott innovation.
Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott. The website that you have requested also may not be optimised for your screen size.
Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.
